DPP4 and type 1 diabetes mellitus: Shao and colleagues (Shao et al, 2020) specifically investigated GLP-1 and GABA pathways after discovering that a DPP-4 inhibitor sitagliptin in combination with GABA increased β-cell mass in the STZ-induced T1D mouse model (Liu et al, 2017).